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Summary—We used a microsimulation model to estimate the threshold body weights at which
screening bone densitometry is cost-effective. Among women aged 55–65 years and men aged
55–75 years without a prior fracture, body weight can be used to identify those for whom bone
densitometry is cost-effective.
Introduction—Bone densitometry may be more cost-effective for those with lower body weight
since the prevalence of osteoporosis is higher for those with low body weight. Our purpose was to
estimate weight thresholds below which bone densitometry is cost-effective for women and men
without a prior clinical fracture at ages 55, 60, 65, 75, and 80 years.
Methods—We used a microsimulation model to estimate the costs and health benefits of bone
densitometry and 5 years of fracture prevention therapy for those without prior fracture but with
femoral neck osteoporosis (T-score≤−2.5) and a 10-year hip fracture risk of ≥3%. Threshold pre-
test probabilities of low BMD warranting drug therapy at which bone densitometry is cost-
effective were calculated. Corresponding body weight thresholds were estimated using data from
the Study of Osteoporotic Fractures (SOF), the Osteoporotic Fractures in Men (MrOS) study, and
the National Health and Nutrition Examination Survey (NHANES) for 2005–2006.
Results—Assuming a willingness to pay of $75,000 per quality adjusted life year (QALY) and
drug cost of $500/year, body weight thresholds below which bone densitometry is cost-effective
for those without a prior fracture were 74, 90, and 100 kg, respectively, for women aged 55, 65,
and 80 years; and were 67, 101, and 108 kg, respectively, for men aged 55, 75, and 80 years.
Conclusions—For women aged 55–65 years and men aged 55–75 years without a prior fracture,
body weight can be used to select those for whom bone densitometry is cost-effective.
Keywords
Body weight; Bone densitometry; Cost-effectiveness; Osteoporosis screening
Introduction
Fractures related to osteoporosis are projected to occur in 3 million US women and men at a
cost of $25 billion by 2025 [1]. Clinical efforts to reduce this burden rely in part on bone
densitometry to select those for whom pharmacologic fracture prevention therapy is
indicated [2]. Most economic modeling studies have focused on the cost-effectiveness of
fracture reduction therapy, but have not considered the upfront cost of screening to estimate
fracture risk. Previous studies show that bone densitometry followed by 5 years of
pharmacologic therapy is cost-effective among women aged ≥65 years [3–5] and in the USA
for men ≥70 years [6]. However, they generally have not considered other factors that affect
the pre-test probability of osteoporosis and therefore the cost of screening, nor have they
addressed appropriate screening strategies at ages less than 65 years. The US Preventive
Services Task Force (USPSTF) estimated that in women without previous vertebral fracture,
the number needed to screen to prevent one hip fracture in 5 years was 1667 in women aged
55–59 years, compared to 556 in women aged 65–69 years [7]. Strategies that screen subsets
of middle-aged individuals with a higher pre-test probability of very low BMD and high
fracture risk are more likely to be cost-effective.
Several validated clinical decision rules can help select those for whom the pre-test
probability of osteoporosis is raised. The Osteoporosis Self-Assessment Tool (OST) uses
only age and body weight to estimate pre-test probability of osteoporosis [8] and performs
as well as other clinical decision rules that incorporate other risk factors [9, 10]. Particularly
for those without a history of fracture, body weight might influence the cost-effectiveness of
bone densitometry. Our objective was to estimate the body weights below which bone
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densitometry is cost-effective for US Caucasian women and men aged 55–80 years without
a prior clinical fracture.
Methods
The validated Markov microsimulation model (Data Pro Healthcare software
[Williamstown, MA]) used for this study is thoroughly described in prior publications [3, 6,
11–14]. Our analyses apply to older Caucasian US women and men who have not had a
prior clinical fracture since age 50 years, and assume a national health payer perspective.
The model health states were no fracture, post-distal forearm fracture, post-clinical vertebral
fracture, post-radiographic vertebral fracture (i.e., not recognized clinically at onset), post-
hip fracture, post-other fractures (i.e., of the proximal forearm, humerus, scapula, clavicle,
sternum, ribs, pelvis, distal femur, patella, tibia, or proximal fibula), post-both hip and
clinical vertebral fracture, and death (Fig. 1). Individuals could transition to a different state
once every 3 months. Individuals aged 55, 60, 65, 70, 75, and 80 years were screened at
baseline and followed until age 100 years or death in order to capture all long-term costs and
disutility from fractures. Models were run as Monte Carlo simulations with 100,000 trials
each, assuming a 3% annual discount rate for costs and health benefits.
Based on a recent cost-effectiveness study [15], most current guidelines in the USA
recommend pharmacologic treatment if the estimated 10-year risks of hip or major
osteoporotic fractures exceed, respectively, 3% or 20% [16]. We used the FRAX fracture
risk calculator [17] to estimate the BMD T-score threshold at which the risk of hip or major
osteoporotic fractures exceeded one of these thresholds for US Caucasian men and women
of average height and weight for their age and sex with no additional fracture risks other
than low BMD. However, the fracture reduction benefit of drug therapy for those with
neither a prevalent vertebral fracture nor a femoral neck BMD T-score ≤−2.5 remains
unproven [18]. Hence, we postulated that drug therapy would be indicated for those with
both a femoral neck T-score ≤−2.5 and either a 10-year estimated hip fracture risk of ≥3% or
major osteoporotic fracture risk of 20% (Table 1). For men, we calculated T-scores using
young male norms.
We assumed a willingness to pay (WTP) threshold of $75,000 per quality adjusted life year
(QALY) gained for the primary analyses, which is roughly twice the per capita gross
domestic product (GDP) of the USA. We based this on the WHO Commission of
Macroeconomics and Health suggesting that a reasonable willingness to pay threshold for a
given country may be one to three times the per capita GDP [19], and on cost-effectiveness
work by Borgstrom and colleagues assuming a societal WTP equal to twice per capita GDP
[20]. However, we also performed analyses assuming WTP thresholds of $50,000 and
$100,000.
Overall analytic strategy
We first used our microsimulation model to estimate the costs per QALY gained for the
intervention strategy compared to no intervention across a wide range of assumed pre-test
probabilities of low BMD warranting drug therapy for each age and sex. Second, we
calculated the pre-test probability threshold for each age and sex at which the cost per
QALY gained would be equal to each of the three WTP thresholds by linear interpolation
between those pre-test probabilities associated with the costs per QALY gained just above
and below each WTP threshold.
Third, for each subset defined by age and sex, we calculated the body weights at which the
pre-test probability of low BMD warranting drug therapy is equal to the pre-test probability
threshold of low BMD below which bone densitometry is cost-effective. The weight
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thresholds were calculated from a) the mean body weight for that subset; b) the mean pre-
test probability of low BMD warranting drug therapy for that subset; c) the pre-test
probability of low BMD at which the intervention strategy is cost-effective; and d) the
association between body weight and the pre-test probability of low BMD. This association
allowed us to translate how much weight change from the mean would correspond to the
change in pre-test probability of low BMD from the mean to the cost-effective threshold
pre-test probability (described in detail in “ Appendix”). We then calculated the body weight
threshold at which bone densitometry is cost-effective by adding or subtracting the weight
change from the mean body weight for that that subset defined by age and sex. Fourth, the
proportion of the population within each subset defined by age and sex below these body
weight thresholds were then calculated using NHANES 2005–2006 data.
We estimated the association of low BMD warranting drug therapy and body weight among
women and men without prior fracture using unpublished data from the second SOF study
visit (7,927 women, mean age 73.7 years) and the baseline MrOS study visit (5,993 men,
mean age 73.7 years). The derivations of the separate logistic regression models for each
treatment cutpoint are described in the technical “Appendix”. Earlier publications have
detailed the recruitment and characteristics of the SOF population attending the second SOF
visit and the MrOS population at the first MrOS visit [21–23].
Model parameters
Mortality rates—Background mortality rates for Caucasian women and men were
estimated from 2004 US vital statistics [24]. The mortality for the first year after hip fracture
attributable to the fracture was estimated to be 0.375 times the background rate [25].
Fracture probabilities—Fracture rate equations for hip and clinical vertebral fractures as
a function of age for each sex were developed from recent data for the US Caucasian
population [26]. We assumed that only 25% of all radiographically detected vertebral
fractures would be clinically recognized at the time of their occurrence and that the rate of
radiographic (but clinically unapparent) vertebral fractures is three times the rate of clinical
vertebral fractures [22]. Fracture rate equations for wrist and other fractures were
constructed from published data [27, 28] as previously described [3, 6, 11]. Since these
fracture rate equations are for all individuals regardless of BMD or prior clinical fracture
status, these rates were adjusted for the absence of a prior clinical fracture and the presence
of BMD below the treatment cutpoint (described in detail in the technical “Appendix”),
based on the relative risks of fracture attributable to low BMD and prior clinical fracture
noted in Table 2. The relative risks of fractures on bisphosphonate therapy based on
published randomized controlled trials [29–34] are shown in Table 2. After a 5-year
treatment course, a gradual linear loss of fracture reduction benefit was assumed to occur
over the subsequent 5 years.
Relative risk of fractures associated with obesity in men—The age-adjusted and
BMD-adjusted relative risks of hip and non-spine fractures in men have been estimated to be
1.76 and 1.29 [35], respectively, for men who are obese (body mass index [BMI] ≥30 kg/
m2) compared to men with BMI ≤25. Hence, for male age groups where the weight below
which bone densitometry is cost-effective is higher than the average weight, the cost-
effectiveness of bone densitometry followed by drug therapy may be underestimated without
taking these increased fracture risks into account. Therefore, models for those male age
groups were re-run with hip and non-hip, non-spine fracture rates raised, respectively, 1.76
and 1.29-fold.
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Costs—The cost of bone density screening per person being treated was calculated as the
mean Medicare reimbursement for the first half of 2010 ($97.41) [36] divided by the
prevalence of BMD below the treatment cutpoint in that subset defined by age and sex. The
prevalence of those with femoral neck BMD below the treatment cutpoint for each starting
age for US Caucasian females and males, regardless of prior clinical fracture status, was
estimated from NHANES 2005–2006 data [37]. However, those without a prior clinical
fracture have higher BMD, and hence these prevalences were adjusted for the absence of a
prior clinical fracture (Table 1). The details of these calculations are given in the technical
“Appendix”.
For the primary and secondary analyses, respectively, we assumed bisphosphonate costs of
$500 and $250 per year. Although the cost of generic alendronate is as low as $100 per year,
in clinical practice some individuals will be switched to other, more expensive agents (most
of which have an average 2010 wholesale drug cost of $1400 to $1600 per year) [38] based
on patient preference or intolerance to alendronate. Assuming a drug cost equal to generic
alendronate is invalid because this implies that patients known to have osteoporosis after
having a bone density test would go untreated if they could not tolerate alendronate. An
aggregate cost of $500 per year would correspond to 70% being treated with generic
alendronate and 30% with other medications, whereas a cost of $250 per year would
correspond to 89% being treated with generic alendronate and 11% with other medications.
The direct medical costs of acute hip, clinical vertebral, distal forearm, and “other” fractures
are expressed in 2010 US dollars (Table 2) [39]. As detailed in previous publications [6, 11],
the proportion of those with an incident hip fracture who are community dwelling before
their hip fracture and require permanent long-term care after their hip fracture was estimated
to be 12.2%, costing $9,055 per year until death averaged over all hip fracture patients (2010
US dollars, Table 2) [40, 41].
Quality adjusted life years (QALYs) associated with each health state—Based
on age-specific US population based values, we assumed a QALY value of 0.84 for those
younger than age 75 years and 0.82 for those aged 75 years and older for the “no fracture”
state [42]. The disutilities for the first and subsequent years after hip, distal forearm, and
clinical vertebral fractures [43], for the first year following other fractures [44], for all
fractures more than 1 year after their occurrence [44], and for those who have had both a hip
and a clinical vertebral fracture [45] are shown in Table 2.
Medication adherence—We assumed that 85% of prescribed medication is purchased
and taken in the first 3 months and that this percentage drops to 65% by the end of 1 year,
60% by the end of the second year, and 55% by the start of the fifth (and final) year of drug
therapy [46]. Medication costs and fracture reduction efficacy were assumed to be
proportional to adherence [47, 48].
Sensitivity analyses—Univariate sensitivity analyses were done varying fracture costs,
rates, and disutility, bone densitometry cost, and the association between weight and odds of
low BMD warranting drug therapy. Since drug therapy may not be acceptable to many
patients unless they are at higher fracture risk than currently accepted treatment thresholds,
we also did sensitivity analyses assuming initiation of treatment only if the 10-year hip
fracture risk is ≥6% (corresponding to femoral neck T-scores of −3.26 and −3.15,
respectively, for 65-year-old Caucasian women and men without prior fracture or other risk
factors). For parameters derived from SOF and MrOS (association between weight and odds
of low BMD warranting drug therapy, proportion with a prior clinical fracture, and odds of
low BMD warranting treatment in those with compared to those without prior clinical
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fracture), sensitivity analyses varying these over wide ranges were also performed for 55-
year-old men and women.
To capture the effect of simultaneous changes of multiple parameters, probabilistic
sensitivity analyses were done (see details of parameter distributions in the technical
“Appendix”).
Results
The mean body weights, the prevalence of femoral neck BMD below the treatment cutpoint
for each age, and the threshold pre-DXA test probability of femoral neck BMD being below
the treatment cutpoint for each age and sex are shown in Table 3 for women and Table 4 for
men, assuming a WTP threshold per QALY gained of $75,000. The pre-test probability of
BMD sufficiently low to warrant pharmacologic therapy such that bone densitometry
followed by pharmacologic therapy would be cost-effective ranged from 1.6% for women
aged 55 years to 1.1% for women aged 70 years and from 15.7% for men aged 55 years to
1.3% for men aged 80 years. The body weight thresholds corresponding to these pre-test
probabilities of low BMD ranged from 73.8 kg for women aged 55 years to 100.2 kg for
women aged 80 years and from 67.2 kg for men aged 55 years to 108.2 kg for men age 80
years.
Assuming a willingness to pay per QALY gained of $75,000 and yearly drug cost of $500,
the proportions of women without a prior clinical fracture aged 55, 65, and 75 at or below
the body weight thresholds such that bone densitometry followed by fracture prevention
therapy was cost-effective were, respectively, 41, 76, and 98% (Fig. 2a). Similarly, bone
densitometry was cost-effective for 10, 51, and 83%, respectively, of men without a prior
clinical fracture at ages 55, 65, and 75 (Fig. 2b). These proportions change modestly under
the assumptions of willingness to pay thresholds of either $50,000 or $100,000 per QALY
gained, or yearly fracture prevention drug cost of $250 per year.
Importantly, the proportion of men and women for whom bone densitometry is cost-
effective is sensitive to changes in treatment threshold. For example, if treatment is offered
(or accepted) only if the 10-year risk of hip fracture is 6%, then the treatment T-score
thresholds for 65-year-old women and men, respectively, are −3.26 and −3.1, and the
proportions for whom bone densitometry is cost-effective fall to 51% and 28% (Fig. 3a, b).
These results are also somewhat sensitive to DXA cost, fracture rates, and fracture disutility.
However, the proportions of men and women aged 55 for whom bone densitometry is cost-
effective change little (<5%) with changes of the prevalence of prior clinical fracture and of
the odds of low BMD warranting treatment. Changes in the association of body weight and
bone mineral density also have little effect on these proportions if the base case estimated
cost-effective body weight threshold is very close to the mean body weight (as for men aged
65, Fig. 3a), but have a larger influence on the estimated body weight threshold if the base
case estimated body weight threshold is quite different from the mean body weight (Fig. 3b).
Varying multiple parameters simultaneously has a greater effect on the estimated
proportions of men for whom bone densitometry is cost-effective than for women, largely
because of greater uncertainty regarding the fracture reduction efficacy of bisphosphonates
in men compared to women.
Discussion
Bone densitometry in the USA is widely recommended at least once for all women aged 65
and older [2, 49, 50] and all men aged 70 and older [2, 50]. Cost-effectiveness evaluations
have lent support to these recommendations [3, 4, 6], consistently showing modest cost
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relative to the health benefits gained for these older individuals. With few exceptions [6, 51],
these studies have not considered the costs and potential health benefits of bone
densitometry for subgroups stratified on risk factors for low bone mass other than age and
sex.
Among Caucasian women between the ages of 55 and 65 and men between the ages of 55
and 75 without a history of a clinical fracture after age 50, our data show that body weight
can aid selection of those for whom it is cost-effective to perform bone densitometry.
However, bone densitometry is cost-effective for virtually all women aged 70 and older and
for men aged 80 years regardless of body weight. Incorporating body weight into electronic
decision tools (embedded in the medical record) as to whether or not a bone density test is
indicated for a specific individual is likely to be feasible. This could reduce the frequency of
measuring BMD on those younger post-menopausal women and men whose likelihood of
having bone mass below a reasonable treatment threshold is very low. While our results are
modestly changed by varying assumptions regarding drug cost and the willingness to pay
threshold per QALY gained, they hold up well under reasonable changes in these
assumptions.
Our suggested body weight thresholds for bone densitometry among women younger than
age 65 years old are somewhat more liberal than levels recommended by the US Preventive
Services Task Force [49]. The USPSTF recommended that bone densitometry be offered to
women younger than age 65 if the pre-test estimated risk of major osteoporosis fracture was
9.3% (calculated using FRAX without BMD), since this is the average risk of 65-year-old
Caucasian women. At the body weight thresholds derived from our analyses for women
aged 55 and 60 of average height and with no other risk factors, the 10-year major
osteoporotic fracture risk is, respectively, 5.3% and 6.3%. Our recommendations are derived
explicitly using cost-effectiveness criteria, whereas those of USPSTF are not.
We chose not to do these analyses within the context of the complete FRAX calculator for
two reasons. First, among all of the FRAX risk factors, age, sex, BMD, and prior fracture
explain the majority of fracture risk in populations where the other risk factors (e.g., current
smoking, parental history of hip fracture, glucocorticoid use, rheumatoid arthritis, heavy
alcohol use) are of low prevalence [52]. Hence, at the population level, for younger post-
menopausal women and men without a prior clinical fracture, subsequent fracture risk will
be driven largely by BMD. Second, the benefit of currently available therapies for
preventing non-vertebral fractures among those with neither osteoporosis by BMD criteria
nor a prevalent vertebral fracture remains unproven. Our results and conclusions would
differ if we assumed that the fracture reduction benefit of drug therapy is unrelated to BMD.
In that instance, there will be subsets with clinical fracture risk factors sufficient to warrant
therapy regardless of BMD [51].
There are limitations to our study. Our results do not apply to individuals who have
additional risk factors for fractures such as current smoking, glucocorticoid use, or chronic
diseases such as COPD or rheumatoid arthritis. Our results are applicable only to Caucasian
women and men who have men not had a prior bone density test, and therefore cannot be
used to estimate when bone densitometry should be repeated. We derived some of our model
parameters from SOF and MrOS which enrolled individuals aged 65 and older, and from
these data estimated these parameters for women and men aged 55–65 by extrapolation. Our
models assume that individuals with a BMD value that correlates with a 10-year hip fracture
risk of 3% or more will at least initially accept a prescription for a fracture prevention
medication. If the majority of such individuals would not accept such treatment, then bone
densitometry may be inappropriate. The estimated thresholds of body weight below which
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bone densitometry is cost-effective are lower if treatment was offered and accepted only at
higher levels of fracture risk.
Finally, our results do not imply that individuals above the body weight thresholds in our
analysis are never at risk of fracture [53]. Bone densitometry may be cost-effective for many
of those heavier than our proposed thresholds if therapies at some point are shown to reduce
fractures significantly in those with neither prevalent vertebral fracture nor osteoporosis by
BMD criteria.
In summary, the cost-effectiveness of bone densitometry for women and men without a
history of fracture is influenced by body weight, largely by its effect on the pre-test
probability of BMD being sufficiently low to warrant drug therapy. Our results suggest that
considering body weight can help identify women between ages 55 and 65 and men between
ages 55 and 75 without additional fracture risk factors for whom a bone densitometry likely
to be cost-effective.
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Appendix
This technical appendix describes in detail the derivation of a) the relative risks of fractures
attributable to the absence of prior clinical fracture; b) the proportion of those without
clinical fracture who have low bone mass warranting drug therapy; c) the relative risks of
fractures attributable to low BMD warranting drug therapy; d) the pre-test probability
cutpoints of low BMD below which bone densitometry followed by fracture prevention
therapy is cost-effective; and e) the body weight thresholds below which the pretest
probability of low BMD warranting drug therapy is high enough such that bone
densitometry is cost-effective.
Relative risk of fracture in those without prior fracture (RRNoPriorFracture vs All)
This relative risk is calculated from the following equation:
(1)
[12]
We assumed the relative risk of incident clinical fracture in those with compared to those
without prior fracture (RRPriorFx vs NoPrior Fx) to be 1.73 and 2.04, respectively, for women
and men [54].
The prevalence of prior clinical fracture at each age for each sex (PrevPriorFx) was
determined in three steps using unpublished second study visit data from the Study of
Osteoporotic Fractures and baseline visit data from the Osteoporotic Fractures in Men
(MrOS). First, prediction equations for the odds of prior clinical fracture as a function of age
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and BMD were derived using logistic regression, as described in a previous publication [6].
We used these same equations to extrapolate estimated prevalences of prior clinical fracture
for those under age 65. Since SOF and MrOS only included women and men aged 65 and
older, we did sensitivity analyses for 55-year-old men and women assuming prevalences of
prior clinical fracture only half that predicted by these equations.
Second, the mean BMD for each age were obtained for Caucasian men and women from
public use NHANES 2005–2006 data files [37]. Third, these mean BMD values were then
entered into the prediction equations to obtain the estimated odds of a prior clinical fracture
for each group defined by age and sex. These odds were converted to prevalences (Table 1)
by the equation:
(2)
Proportions of those without prior clinical fracture with bone density below
treatment cutpoints
The prevalence of femoral neck BMD below the treatment cutpoints for each starting age in
the female and male Caucasian US population was estimated from NHANES 2005–2006
data (labeled PrevBMD≤Cutpoint, All in Eq. 3) [37]. This is then converted to an odds by the
following equation:
(3)
To estimate these proportions for the subsets without prior clinical fracture, we first
estimated (using logistic regression models) the age-adjusted odds of femoral neck BMD
below the treatment cutpoints in those with compared to those without prior clinical fracture
(ORBMD≤Cutpoint, PriorFx vs NoPriorFx) for women and men using unpublished second study
visit data from SOF (7,927 women, mean age 73.7 years) and baseline visit data from MrOS
(5,993 men, mean age 73.7 years).
The odds ratio (OR) for low BMD in those without prior clinical fracture compared to the
entire subset of same age and sex is then
(4)
where PrevPriorFx is the prevalence of prior clinical fracture since age 50 for that age and
sex, and ORBMD≤Cutpoint, PriorFx vs NoPriorFx is 1.91 for men, 1.97 for women when the BMD
T-score cutpoint is −2.5, and 2.10 for women when the BMD T-score cutpoint is −2.6 or
lower.
The odds of BMD sufficiently low to warrant drug therapy is then given by the equation:
(5)
The prevalence of femoral neck BMD below the treatment cutpoints for those in each subset
defined by age and sex without prior clinical fracture (PrevBMD≤Cutpoint, NoPriorFx) is then
calculated from the odds (OddsBMD≤Cutpoint, NoPriorFx) using Eq. 2.
The Z-score cutpoint of low BMD (Zcut) corresponding to this prevalence is then calculated
from the normal distribution function.
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Fracture risks attributable to low bone density
The mean Z-scores of those below the Z-score cutpoints were then calculated using the
inverse Mills ratio (Table 1):
(6)
For each fracture type, the relative risk of incident fracture in those with a femoral neck
BMD T-score below the treatment cutpoint was equal to a−Z, where Z is the mean Z-score
for those with BMD below the treatment cutpoint (Table 1), and a is the relative risk of
fracture per standard deviation (SD) decrease in femoral neck Z-score.
The relative risks of hip fracture for each SD decrease in femoral neck BMD, derived from a
large meta-analysis of hip fracture predictors [55], were assumed to decrease with age from
3.29 and 3.92, respectively, for women and men aged 55 years to 2.24 and 2.67,
respectively, for women and men aged 80 years (Table 2). The relative risks of hip fracture
in those with compared to those without prior clinical fracture were assumed to decrease
with age from 3.83 and 4.84 for women and men aged 55 years to 1.36 and 1.71 for women
and men aged 80 years [54]. For women, we assumed relative risks for incident vertebral
fracture of 1.32 in those with compared to those without prior fracture [56] and 1.9 per SD
decrease in femoral neck BMD [57]. The relative risks of non-vertebral non-hip fractures
per SD decrease in femoral neck BMD were assumed to be 1.34 and 1.44, respectively, in
men [58] and women [57]. Using Rotterdam study data, for men we assumed relative risks
for incident vertebral fractures of 1.8 per SD decrease of femoral neck BMD and 2.4 in
those with compared to those without prior clinical fracture [59].
Estimation of weight thresholds below which bone densitometry is cost-
effective
To calculate the weight threshold below which bone densitometry is cost-effective, we start
with the prevalence (pre-test probability) of low bone density warranting drug therapy for
the age-specific and sex-specific subgroup without prior fracture, and the threshold pre-test
prevalence of low bone density at which bone densitometry becomes cost-effective for that
subgroup (columns 2 and 3, Table 5 [women] and Table 6 [men]). These prevalences are
converted to odds (columns 4 and 6) by the equation:
(7)
Since the change of the odds of low BMD warranting drug therapy per change in body
weight is linear in the natural logarithm scale, we then take the logs of these odds (columns
5 and 7). The difference in log(Odds) between these two=[log(Oddsthreshold)
−log(Oddsage, sex)] (column 8).
The age-adjusted association between body weight and odds of femoral neck BMD below
the treatment cutpoint among Caucasians (ORper10 kg weight change) was estimated using
unpublished data from the baseline visit of the MrOS study (for men) and the second study
visit of the SOF visit (for women) with separate logistic regression models for each
treatment cutpoint (column 9, Tables 5 and 6). These odds ratios were 0.30, 0.33, 0.39, and
0.42, respectively, for women aged 55, 60, 65, and 70 years and older, and were 0.40 and
0.44, respectively, for men younger than age 60 and age 65 and older (column 6, Tables 5
and 6).
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The weight change (in kilogram, column 10) required for the odds of low bone density
warranting drug therapy to change from the mean for that age-specific and sex-specific
subgroup to the threshold for cost-effectiveness is equal to the difference in log-odds





Probabilistic sensitivity analyses: distributions
Fracture costs were assumed to follow a log-normal distribution (Table 7), based on the
distribution from the study of Gabriel and colleagues [39]. The proportion of individuals
requiring long-term care beyond the first year after hip fracture was estimated to be 12% (38
out of 312 individuals), and this was assumed to follow a binomial distribution. A normal
approximation to this yields a point estimate for long-term care costs of $9,057 (2010 US
dollars) per year with a standard deviation of $1,103.
We constructed distributions for fracture rates by first assuming that the distributions of the
proportions of individuals at risk who have a first distal forearm, clinical vertebral, or hip
fracture within each specified age range [27] are binomial. The 95% confidence intervals
can be calculated using an exact method appropriate for proportions close to zero [60]. If a
normal approximation to these distributions is then assumed, the standard deviation for these
proportions ranges from 30% for vertebral fracture between ages 65 and 69 to 10.9% for hip
fracture after age 85. For the probabilistic sensitivity analysis, an additional normally
distributed variable was created with mean value of 1.0 and standard deviation equal to 0.22.
This is then multiplied by all of the fracture rates, so that fracture rates vary together over a
normal distribution with the means equal to the point estimates rendered by the fracture risk
equations.
Because of significant uncertainty regarding disutility from fractures, we assumed a uniform
distribution for these to vary from between 50% and 150% of the base case disutility. The
relative risks for hip, non-spine non-hip, and vertebral fractures attributable to osteoporosis
or prior clinical fracture were assumed to be log-normal (since hazard ratios and odds ratios
are linear in the logarithmic scale), as were the relative risks of fractures on oral
bisphosphonates compared to no drug therapy.
Performance of probabilistic sensitivity analyses
The analyses were done with 500 simulations, with 10,000 trials per simulation. For each
simulation, the parameter values are selected randomly from the above distributions. These
analyses were repeated over a wide range of assumed prevalences of low bone density
warranting drug therapy. We then determined, by linear interpolation, the threshold cost-
effective low BMD prevalences (assuming a willingness to pay of $75,000 per QALY
gained and a yearly drug cost of $500) using the 25th and 75th percentiles of costs per
QALY gained. The corresponding weight thresholds were calculated for each of these two
prevalences, and the proportion of the population of that age and sex below each of the two
weight thresholds calculated as shown previously. The difference between these weight
Schousboe et al. Page 11













thresholds represents the interquartile range for the body weights at which bone
densitometry is cost-effective for subgroup without prior fracture defined by age and sex.
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State diagram of Markov model. Transition to death may also occur from any state (not
shown with arrows)
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Proportion of women (a) and men (b) without prior fracture for whom bone densitometry
followed by fracture prevention therapy is cost-effective. *Proportion cost-effective is the
proportion with a body weight below the threshold weight in kilogram (label at top of bars)
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Sensitivity analyses: effect of parameter changes on proportions of women (a) and men (b)
aged 65 without prior fracture for whom bone densitometry is cost-effective. *Ten-year hip
fracture risk treatment threshold varied from 6 to 3%; **Odds ratio of femoral neck
osteoporosis per 10kg increase body weight varied from 0.22 to 0.65; ***Fracture disutility
varied from 50 to 150% of base case value; ^Fracture costs varied from 70 to 130% of base
case value; ^^Fracture rates varied from 80 to 120% of base case value; ^^^From
probabilistic sensitivity analyses (see “Appendix”). Vertical line represents base vase
proportion for whom bone densitometry is cost-effective
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 No fracture state 0 Peasgood [43]
 Post-distal forearm fracture 0.04 (1st year), then 0
 Post-hip fracture 0.20 1st year, then 0.131 years 2–5
 Post-clinical vertebral fracture 0.23 1st year), then 0.064 years 2–5
 Post-radiographic vertebral fracture 0.126 1st year, then 0.06 years 2–5 Kanis [44]
 Post-hip and clinical vertebral fracture 0.36 (1st year), then 0.20 years 2–10 Tosteson [45]
 Post-“other” fracture 0.073 (1st year), then 0.023 years 2–5 Kanis [44]
Direct medical costs
 Acute hip fracture $35,322
  Direct medical costs $23,455 Gabriel [39]
  1st year long-term care $11,867 Leibson [40]
 Acute clinical vertebral fracture $9,244 Gabriel [39]
 Acute radiographic (clinically unapparent) vertebral fracture $0 Gabriel [39]
 Acute distal forearm fracture $5,017 Gabriel [39]
 Acute other fracture $7,264 Gabriel [37]
 Annual long-term care>1 year after hip fracture $9,057 Leibson [40]
Relative risk of fractures on bisphosphonate therapy Men: non-spine fractures 0.73, spine
fractures 0.36. Women: vertebral 0.5; hip,
wrist 0.60; other 0.80
Orwoll [61], Ringe [62],
Sawka [34], Black [30]
Relative risks fractures due to low BMDa Men Women
 Hip
  Age 55 3.92 3.29
  Age 60 3.59 3.01
  Age 65 3.38 2.83
  Age 70 3.25 2.73
  Age 75 3.02 2.53
  Age 80 2.67 2.24
  Age 85 2.26 1.89
 Wrist and other 1.34 1.40
 Vertebral 1.80 1.90
Relative risks fractures prior clinical fracture vs no prior fracture Men Women
 Hip
  Age 55 4.84 3.83
  Age 60 3.84 3.04
  Age 65 2.77 2.20
  Age 70 2.31 1.83
  Age 75 1.99 1.58
  Age 80 1.71 1.36
  Age 85 1.61 1.27
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Parameter Value References
 Wrist and other 2.01 1.73
 ∘Vertebral 2.40 1.32
a
Per SD decrease of femoral neck BMD
*
QALY value for health state is 0.84 for those age <75 years and 0.82 age 75 and older. Disutilities are represent difference in QALY value
between healthy and other states
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Table 7
Distributions for parameters allowed to vary in probabilistic sensitivity analyses
Parameter Distribution Mean (95% CI or range)
Cost of hip fracture Log normal $35,320 (22,010–56,678)
Cost of spine fracture Log normal $9,244 (2,230–38,318)
Cost of distal forearm fracture Log normal $4,928 (692–35,102)
Cost of other fractures Log normal $7,264 (1,707–30,901)
Long-term care costs Normal $9,057 (6,556–11,558)
Disutility of fractures Uniform 50–150% of base case values
Fracture rates Normal Standard deviation 22% of mean rate
Vertebral fracture drug efficacy Log normal Men: 0.36 (0.22–0.59); women: 0.40 (0.20–0.80)
Non-vertebral fracture drug efficacy Log normal Men: 0.73 (0.53–0.99)
Hip fracture drug efficacy Log normal Women: 0.60 (0.38–0.94)
Wrist fracture drug efficacy Log normal Women: 0.6 (0.44–0.81)
Other fracture drug efficacy Log normal Women: 0.8 (0.65–0.99)
Association of hip fracture with prior fracture (logHR) Log normal Men: 2.77 (2.22–3.46); women: 2.20 (1.47–3.29)
Association of Hip Fracture with 1 SD change of BMD (logHR) Log normal Men: 3.38 (2.65–4.30); women: 2.83 (2.34–3.43)
Association of vertebral fracture with prior fracture (logOR) Log normal Men: 2.40 (1.20–4.80); women: 1.32 (1.00–1.78)
Association of vertebral fracture with 1 SD change of BMD (logOR) Log normal Men: 1.80 (1.28–2.54); women: 1.90 (1.48–2.45)
Association of Wrist/Other Fracture with Prior Fracture (logHR) Log normal Men: 2.04 (1.61–2.59); women: 1.73 (1.57–1.91)
Association of wrist/other fracture with 1 SD change of BMD (logHR) Log normal Men: 1.34 (1.17–1.53); women: 1.44 (1.39–1.49)
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